Clinical pharmacokinetics of second generation antisense oligonucleotides

A phase I trial of AEG35156 (XIAP antisense) administered as 2-hour intravenous infusions in patients with advanced tumours

(2017) J. Jolivet et al.   JOURNAL OF CLINICAL ONCOLOGY

Antisense oligonucleotides for the treatment of dyslipidaemia

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Abstract B48: A phase 1 study of an antisense oligonucleotide against survivin (LY2181308) in Japanese patients with solid tumors

(2012) H. Nokihara et al.   MOLECULAR CANCER THERAPEUTICS

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer

(2011) Janessa J. Laskin et al.   Journal of Thoracic Oncology

Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes

(2011) Erich Koller et al.   NUCLEIC ACIDS RESEARCH

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

(2010) M. Tanioka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

(2010) D. C. Talbot et al.   CLINICAL CANCER RESEARCH

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

In Vitro Metabolic Stabilities and Metabolism of 2′-O-(Methoxyethyl) Partially Modified Phosphorothioate Antisense Oligonucleotides in Preincubated Rat or Human Whole Liver Homogenates

(2010) Min-Son Baek et al.   OLIGONUCLEOTIDES

Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN

(2009) Richard S. Geary et al.   BIOCHEMICAL PHARMACOLOGY

Antisense oligonucleotide pharmacokinetics and metabolism

(2009) Richard S Geary   Expert Opinion on Drug Metabolism & Toxicology

Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia

(2009) Aaron D. Schimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer

(2009) Emma Dean et al.   JOURNAL OF CLINICAL ONCOLOGY

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

(2008) Rosie Z. Yu et al.   BIOCHEMICAL PHARMACOLOGY

A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

(2008) K. N. Chi et al.   CLINICAL CANCER RESEARCH

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS

Oligonucleotidic therapeutics

(2008) Yoshitaka Isaka et al.   Expert Opinion on Drug Discovery

Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?

(2008) Vasilios G Athyros et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Very late antigen-4 integrin antagonists

(2008) Jefferson W Tilley   EXPERT OPINION ON THERAPEUTIC PATENTS

On the Volume of Distribution at Steady State and Its Relationship With Two‐Compartmental Models

(2007) James W.T. Yates et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Oral Delivery of Antisense Oligonucleotides in Man

(2007) Lloyd G. Tillman et al.   JOURNAL OF PHARMACEUTICAL SCIENCES